Výsledky vyhledávání - "Massimiliano Germani"

Akademický článek

Preclinical Studies in the mdx Mouse Model of Duchenne Muscular Dystrophy with the Histone Deacetylase Inhibitor Givinostat

Autor: Silvia Consalvi, Chiara Mozzetta, Paolo Bettica, Massimiliano Germani, Francesco Fiorentini, Francesca Del Bene, Maurizio Rocchetti, Flavio Leoni, Valmen Monzani, Paolo Mascagni, Pier Lorenzo Puri, Valentina Saccone

Publikováno v: Molecular Medicine, Vol 19, Iss 1, Pp 79-87 (2013)

Abstract Previous work has established the existence of dystrophin-nitric oxide (NO) signaling to histone deacetylases (HDACs) that is deregulated in dystrophic muscles. As such, pharmacological interventions that target HDACs (that is, HDAC inhibito

Externí odkaz: https://doaj.org/article/228636ca172f4dd983eb3ef54f6caf4d

Zobrazit plný text záznamu

Supplementary Figure S2 from NMS-E973, a Novel Synthetic Inhibitor of Hsp90 with Activity against Multiple Models of Drug Resistance to Targeted Agents, Including Intracranial Metastases

Supplementary Figure S2 - PDF file 456K, Time-lapse imaging of A375 cells treated with NMS-E973

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f283c674905df024deea1ce236ca7aa
https://doi.org/10.1158/1078-0432.22451829.v1

Zobrazit plný text záznamu

Supplementary Table S1 from NMS-E973, a Novel Synthetic Inhibitor of Hsp90 with Activity against Multiple Models of Drug Resistance to Targeted Agents, Including Intracranial Metastases

Supplementary Table S1 - PDF file 94K, Antiproliferative activity of NMS-E973

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d89fb90cbe5dad008cd241246f1ef48
https://doi.org/10.1158/1078-0432.22451817.v1

Zobrazit plný text záznamu

Data from NMS-E973, a Novel Synthetic Inhibitor of Hsp90 with Activity against Multiple Models of Drug Resistance to Targeted Agents, Including Intracranial Metastases

Purpose: Recent developments of second generation Hsp90 inhibitors suggested a potential for development of this class of molecules also in tumors that have become resistant to molecular targeted agents. Disease progression is often due to brain meta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0947fcab05687d15962c1dd2f2c4d7a7
https://doi.org/10.1158/1078-0432.c.6522303.v1

Zobrazit plný text záznamu

Supplementary Methods from NMS-E973, a Novel Synthetic Inhibitor of Hsp90 with Activity against Multiple Models of Drug Resistance to Targeted Agents, Including Intracranial Metastases

Supplementary Methods - PDF file 56K, Time-lapse imaging of A375 cells

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::890811bb8dc8943c26d3ed639f1dc414
https://doi.org/10.1158/1078-0432.22451820

Zobrazit plný text záznamu

Phase 1/1b Studies of UCB0599, an Oral Inhibitor of α-Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease

Autor: Johan Willem Smit, Peter Basile, Maria Key Prato, Laurent Detalle, François‐Xavier Mathy, Astrid Schmidt, Marianna Lalla, Massimiliano Germani, Coralie Domange, Anja‐Leona Biere, Massimo Bani, Stan Carson, Just Genius

Publikováno v: Movement disorders : official journal of the Movement Disorder Society. 37(10)

Parkinson's disease (PD) and its progression are thought to be caused and driven by misfolding of α-synuclein (ASYN). UCB0599 is an oral, small-molecule inhibitor of ASYN misfolding, aimed at slowing disease progression.The aim was to investigate sa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd0af038c0c9daf39a2c798645ebce9f
https://pubmed.ncbi.nlm.nih.gov/35959805

Zobrazit plný text záznamu

An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal models

Autor: Iebe Rossey, Sandrine Vanmarcke, Sieglinde De Cae, Joana Rocha-Pereira, Xavier Saelens, Martin Schwemmle, Wander Van Breedam, Andrew Popplewell, Nick Devoogdt, Laurens Liesenborghs, Dominique Tersago, Annette Ohnemus, Kenny Roose, Simon Devos, Julius Beer, Piet Maes, Frank Peelman, Daniel Schnepf, Peter Staeheli, Sofie Jacobs, Wim Nerinckx, Massimiliano Germani, Catelijne Stortelers, George D. Moschonas, Kevin Brady, Alison Turner, Rana Abdelnabi, Daria Fijalkowska, Wannes Weyts, Isabel Remory, Leen Delang, Lana Langendries, Laura Seldeslachts, João Paulo Portela Catani, Bruno Dombrecht, Dries Van Herpe, Dirk Jochmans, Loes van Schie, Koen Sedeyn, Greetje Vande Velde, Chiara Lonigro, Sarah Creytens, Xin Zhang, Bert Schepens, Sebastiaan ter Horst, Kai Dallmeier, Hannah Eeckhaut, Caroline Shi-Yan Foo, Jimmy Borloo, Robbert Boudewijns, Suzanne J.F. Kaptein, James Heads, Nico Callewaert, Birgit Weynand, Mark Ellis, Ana Filipa Oliveira, Annelies Van Hecke, Gitte Michielsen, Dorien De Vlieger, Jackeline Cecilia Zavala Marchan, Alistair Henry, Johan Neyts, Hendrik Jan Thibaut

Publikováno v: SCIENCE TRANSLATIONAL MEDICINE

Broadly neutralizing antibodies are an important treatment for individuals with coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Antibody-based therapeutics are also essential for pandemic pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3830e9b60d433a409a79548892804d43
https://lirias.kuleuven.be/handle/123456789/682263

Zobrazit plný text záznamu

Padsevonil randomized Phase IIa trial in treatment-resistant focal epilepsy: a translational approach

Autor: Jonas Hannestad, Bernhard J. Steinhoff, Massimiliano Germani, Koen Van Laere, Konrad J. Werhahn, Christian Otoul, David Sciberras, Manuel Toledo, Christian Brandt, Rafal M. Kaminski, Marian Majoie, Steven DeBruyn, Pierandrea Muglia, Wim Van Paesschen, Brigitte Lacroix, Elizabeth Webster

Publikováno v: Brain Communications
Brain Communications, 2(2):183. Oxford University Press

Therapeutic options for patients with treatment-resistant epilepsy represent an important unmet need. Addressing this unmet need was the main factor driving the drug discovery program that led to the synthesis of padsevonil, a first-in-class antiepil

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f729a1db940c38ae2356fe351d63866
https://doi.org/10.1093/braincomms/fcaa183

Zobrazit plný text záznamu

A Minimal Model of Tumor Growth Inhibition in Combination Regimens Under the Hypothesis of No Interaction Between Drugs

Autor: Massimiliano Germani, Nadia Terranova, Paolo Magni, G. De Nicolao, F. Del Bene

Publikováno v: IEEE Transactions on Biomedical Engineering. 59:2161-2170

One important issue in the preclinical development of an anticancer drug is the assessment of the compound under investigation when administered in combination with other drugs. Several experiments are routinely conducted in xenograft mice to evaluat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87a77a7aa43c5440e454daa3cd5a819d
https://doi.org/10.1109/tbme.2012.2197680

Zobrazit plný text záznamu

Testing additivity of anticancer agents in pre-clinical studies: A PK/PD modelling approach

Autor: Italo Poggesi, Enrico Pesenti, Massimiliano Germani, Francesco Fiorentini, F. Del Bene, G. De Nicolao, M. Rocchetti, Paolo Magni

Publikováno v: European Journal of Cancer. 45:3336-3346

In clinical oncology, combination regimens may result in a synergistic, additive or antagonistic interaction (i.e. the effect of the combination is greater, similar or smaller than the sum of the effects of the individual compounds). For this reason,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7894a6c18076b3bd16a71668e905b42c
https://doi.org/10.1016/j.ejca.2009.09.025

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání